These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

936 related articles for article (PubMed ID: 30670424)

  • 21. Activity of ceftazidime/avibactam against problem Enterobacteriaceae and Pseudomonas aeruginosa in the UK, 2015-16.
    Livermore DM; Meunier D; Hopkins KL; Doumith M; Hill R; Pike R; Staves P; Woodford N
    J Antimicrob Chemother; 2018 Mar; 73(3):648-657. PubMed ID: 29228202
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular Characterization of Carbapenem-Nonsusceptible Enterobacterial Isolates Collected during a Prospective Interregional Survey in France and Susceptibility to the Novel Ceftazidime-Avibactam and Aztreonam-Avibactam Combinations.
    Dupont H; Gaillot O; Goetgheluck AS; Plassart C; Emond JP; Lecuru M; Gaillard N; Derdouri S; Lemaire B; Girard de Courtilles M; Cattoir V; Mammeri H
    Antimicrob Agents Chemother; 2016 Jan; 60(1):215-21. PubMed ID: 26482307
    [TBL] [Abstract][Full Text] [Related]  

  • 23.
    Lob SH; Karlowsky JA; Young K; Motyl MR; Hawser S; Kothari ND; Sahm DF
    J Med Microbiol; 2020 Feb; 69(2):207-217. PubMed ID: 31976856
    [No Abstract]   [Full Text] [Related]  

  • 24. In Vitro Susceptibility of Global Surveillance Isolates of Pseudomonas aeruginosa to Ceftazidime-Avibactam (INFORM 2012 to 2014).
    Nichols WW; de Jonge BL; Kazmierczak KM; Karlowsky JA; Sahm DF
    Antimicrob Agents Chemother; 2016 Aug; 60(8):4743-9. PubMed ID: 27216074
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessment of the
    Viala B; Zaidi FZ; Bastide M; Dumont Y; Le Moing V; Jean-Pierre H; Godreuil S
    Microb Drug Resist; 2019 Nov; 25(9):1325-1329. PubMed ID: 31225764
    [No Abstract]   [Full Text] [Related]  

  • 26. The ERACE-PA Global Surveillance Program: Ceftolozane/tazobactam and Ceftazidime/avibactam in vitro Activity against a Global Collection of Carbapenem-resistant Pseudomonas aeruginosa.
    Gill CM; Aktaþ E; Alfouzan W; Bourassa L; Brink A; Burnham CD; Canton R; Carmeli Y; Falcone M; Kiffer C; Marchese A; Martinez O; Pournaras S; Satlin M; Seifert H; Thabit AK; Thomson KS; Villegas MV; Nicolau DP;
    Eur J Clin Microbiol Infect Dis; 2021 Dec; 40(12):2533-2541. PubMed ID: 34291323
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ceftazidime-avibactam activity when tested against ceftazidime-nonsusceptible Citrobacter spp., Enterobacter spp., Serratia marcescens, and Pseudomonas aeruginosa from Unites States medical centers (2011-2014).
    Sader HS; Castanheira M; Farrell DJ; Flamm RK; Jones RN
    Diagn Microbiol Infect Dis; 2015 Dec; 83(4):389-94. PubMed ID: 26162518
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Global Dissemination of blaKPC into Bacterial Species beyond Klebsiella pneumoniae and In Vitro Susceptibility to Ceftazidime-Avibactam and Aztreonam-Avibactam.
    Kazmierczak KM; Biedenbach DJ; Hackel M; Rabine S; de Jonge BL; Bouchillon SK; Sahm DF; Bradford PA
    Antimicrob Agents Chemother; 2016 Aug; 60(8):4490-500. PubMed ID: 27161636
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ceftazidime/avibactam tested against Gram-negative bacteria from intensive care unit (ICU) and non-ICU patients, including those with ventilator-associated pneumonia.
    Sader HS; Castanheira M; Flamm RK; Mendes RE; Farrell DJ; Jones RN
    Int J Antimicrob Agents; 2015 Jul; 46(1):53-9. PubMed ID: 25956844
    [TBL] [Abstract][Full Text] [Related]  

  • 30.
    Karlowsky JA; Kazmierczak KM; de Jonge BLM; Hackel MA; Sahm DF; Bradford PA
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630192
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activity of Ceftazidime-Avibactam against Extended-Spectrum- and AmpC β-Lactamase-Producing Enterobacteriaceae Collected in the INFORM Global Surveillance Study from 2012 to 2014.
    Karlowsky JA; Biedenbach DJ; Kazmierczak KM; Stone GG; Sahm DF
    Antimicrob Agents Chemother; 2016 May; 60(5):2849-57. PubMed ID: 26926635
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phenotypic and genotypic profile of ceftolozane/tazobactam-non-susceptible, carbapenem-resistant Pseudomonas aeruginosa.
    Gill CM; Nicolau DP;
    J Antimicrob Chemother; 2022 Dec; 78(1):252-256. PubMed ID: 36411249
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antimicrobial activity of ceftazidime-avibactam against Gram-negative organisms collected from U.S. medical centers in 2012.
    Sader HS; Castanheira M; Flamm RK; Farrell DJ; Jones RN
    Antimicrob Agents Chemother; 2014; 58(3):1684-92. PubMed ID: 24379201
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro activity of ceftazidime/avibactam against isolates of carbapenem-non-susceptible Enterobacteriaceae collected during the INFORM global surveillance programme (2015-17).
    Spiliopoulou I; Kazmierczak K; Stone GG
    J Antimicrob Chemother; 2020 Feb; 75(2):384-391. PubMed ID: 31742604
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Resistance to ceftazidime-avibactam and other new β-lactams in
    Valzano F; La Bella G; Lopizzo T; Curci A; Lupo L; Morelli E; Mosca A; Marangi M; Melfitano R; Rollo T; De Nittis R; Arena F
    Microbiol Spectr; 2024 Aug; 12(8):e0426623. PubMed ID: 38934607
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro activity of ceftazidime/avibactam and comparators against carbapenemase-producing Enterobacterales and Pseudomonas aeruginosa isolates collected globally between 2016 and 2018.
    Kiratisin P; Kazmierczak K; Stone GG
    J Glob Antimicrob Resist; 2021 Dec; 27():132-141. PubMed ID: 34478880
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro activity of ceftazidime-avibactam against clinical isolates of Enterobacterales and Pseudomonas aeruginosa collected in Malaysia: Results from the ATLAS Programme, 2013 to 2019.
    Tuan Soh TS; Salvinder S; Chen VSY
    Med J Malaysia; 2022 Mar; 77(2):174-184. PubMed ID: 35338624
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antimicrobial Activities of Ceftazidime-Avibactam and Comparator Agents against Clinical Bacteria Isolated from Patients with Cancer.
    Hachem R; Reitzel R; Rolston K; Chaftari AM; Raad I
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28115350
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Longitudinal analysis of the in vitro activity of ceftazidime-avibactam vs. Pseudomonas aeruginosa, 2012-2016.
    Stone GG; Smayevsky J; Kazmierczak K
    Diagn Microbiol Infect Dis; 2020 Jan; 96(1):114835. PubMed ID: 31648801
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular characterization of clinically isolated
    Li H; Oliver A; Shields RK; Kamat S; Stone G; Estabrook M
    Antimicrob Agents Chemother; 2024 Oct; 68(10):e0067024. PubMed ID: 39254297
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 47.